for people ages 18-75 (full criteria)
at La Jolla, California and other locations
study started
estimated completion



This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 [NCT02217475] or the AURORA study [NCT03028740].

Official Title

Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)


Nonalcoholic Steatohepatitis Liver Cirrhosis Non-alcoholic Fatty Liver Disease Liver Diseases Fatty Liver TAK-652 Cenicriviroc


You can join if…

Open to people ages 18-75

  • Successful completion of both Treatment Period 1 and Treatment Period 2, of the CENTAUR Study (652-2-203), including a Year 2 liver biopsy.
  • Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated liver-related clinical outcome in Part 1 or Part 2 of the study of:
  • Histopathological progression to cirrhoses
  • Model for end-stage liver disease (MELD) score ≥ 15
  • Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a diuretic)
  • Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed, hepatic encephalophathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid bacterial culture)

You CAN'T join if...

  • Prior or planned liver transplantation
  • Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's disease, hemochromatosis, or iron overload, or Alpha-1-antitrypsis (A1AT) deficiency.


  • University of California, San Diego (UCSD)
    La Jolla California 92037 United States
  • University of California, San Diego (UCSD) - Medical Center
    San Diego California 92093 United States


accepting new patients by invitation only
Start Date
Completion Date
Tobira Therapeutics, Inc.
Phase 2
Study Type
Last Updated